PBYI - NASDAQ
Puma Biotechnology, Inc.
$6.81
-2.4%Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
At a Glance
Live SnapshotPuma Biotechnology, Inc. Management Team
Mr. Maximo F. Nougues
Chief Financial Officer & Principal Accounting Officer
Compensation
$854,153
Mr. Douglas Hunt B.Sc., FRAPS
Chief Regulatory Affairs, Medical Affairs, Pharmacovigilance & Law Officer
Compensation
$735,530
Mr. Alan H. Auerbach
Founder, Chairman, President, Chief Executive Officer & Secretary
Compensation
$1,859,029
Mr. Mariann Ohanesian
Senior Director of Investor Relations
Puma Biotechnology, Inc. Insider Positioning
During the last 12 months, insiders have sold $1.05M worth of PBYI shares, with no buying activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
54.9K
321.76K
-322K
-$322K
6-9 Months
0
0.00
20.0K
97.23K
-97K
-$97K
9-12 Months
0
0.00
183.2K
630.45K
-630K
-$630K
Top Buyers
No buying activity
Top Sellers
Auerbach Alan H
Director, 10 Percent Owner, Officer: President And Ceo
$372K
Cesano Alessandra
Director
$132K
Nougues Maximo F
Officer: Chief Financial Officer
$98K
Miller Michael Patrick
Director
$97K
Senderowicz Adrian
Director
$92K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $1.05M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Insider Participation
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
SEC Filings
PBYI - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 11, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 28, 2025 | June 11, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | June 18, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 28, 2023 | April 28, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 29, 2022 | June 14, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 26, 2021 | June 15, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 27, 2020 | June 09, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 29, 2019 | June 10, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 30, 2018 | June 12, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 28, 2017 | June 12, 2017 | 2017 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.